NovaBay Pharmaceuticals (NBY)
(Delayed Data from AMEX)
$0.49 USD
-0.01 (-1.52%)
Updated Aug 30, 2024 03:58 PM ET
After-Market: $0.49 0.00 (0.68%) 7:24 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Cash flow Statements
Fiscal Year End for NovaBay Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -9.64 | -10.61 | -5.82 | -11.04 | -9.66 |
Depreciation/Amortization & Depletion | 4.49 | 7.22 | 0.12 | 0.05 | 0.07 |
Net Change from Assets/Liabilities | 0.75 | 0.53 | -0.04 | 0.21 | 1.20 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 0.27 | -3.80 | -3.45 | 6.06 | 0.46 |
Net Cash From Operating Activities | -4.13 | -6.65 | -9.19 | -4.72 | -7.93 |
Property & Equipment | -0.02 | -0.11 | -0.05 | -0.03 | -0.02 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | -11.99 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -0.02 | -0.11 | -12.05 | -0.03 | -0.02 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.57 | 4.74 | 16.68 | 12.33 | 9.56 |
Issuance (Repayment) of Debt | 1.53 | 0.00 | 0.00 | -1.56 | 1.35 |
Increase (Decrease) Short-Term Debt | 0.00 | -0.11 | 0.11 | -1.00 | 1.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.18 | 0.00 | 0.00 | 0.00 | -0.20 |
Net Cash from Financing Activities | 1.91 | 4.63 | 16.79 | 9.76 | 11.70 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -2.24 | -2.13 | -4.45 | 5.02 | 3.75 |
Cash at Beginning of Period | 5.85 | 7.98 | 12.43 | 7.41 | 3.66 |
Cash at End of Period | 3.61 | 5.85 | 7.98 | 12.43 | 7.41 |
Diluted Net EPS | -138.46 | -353.15 | -183.38 | -378.99 | -586.83 |
Fiscal Year End for NovaBay Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -4.80 | -3.21 | -9.64 | -5.53 | -3.78 |
Depreciation/Amortization & Depletion | 0.02 | 0.01 | 4.49 | 1.27 | 0.56 |
Net Change from Assets/Liabilities | 0.29 | 0.06 | 0.75 | 0.21 | -0.41 |
Net Cash from Discontinued Operations | 0.12 | 0.12 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 2.22 | 1.45 | 0.27 | 0.23 | 0.17 |
Net Cash From Operating Activities | -2.15 | -1.57 | -4.13 | -3.82 | -3.45 |
Property & Equipment | 0.00 | 0.00 | -0.02 | -0.02 | -0.02 |
Acquisition/ Disposition of Subsidiaries | 1.07 | 1.07 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 1.07 | 1.07 | -0.02 | -0.02 | -0.02 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.23 | 0.00 | 0.57 | 0.00 | 0.00 |
Issuance (Repayment) of Debt | -1.20 | -0.58 | 1.53 | 2.23 | 2.81 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.12 | -0.02 | -0.18 | -0.29 | -0.29 |
Net Cash from Financing Activities | -1.09 | -0.60 | 1.91 | 1.94 | 2.51 |
Effect of Exchange Rate Changes | -0.21 | -0.21 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -2.38 | -1.31 | -2.24 | -1.90 | -0.96 |
Cash at Beginning of Period | 3.61 | 3.61 | 5.85 | 5.85 | 5.85 |
Cash at End of Period | 1.23 | 2.30 | 3.61 | 3.95 | 4.89 |
Diluted Net EPS | -1.37 | -5.24 | -51.40 | -12.94 | -44.41 |